Free Trial
NASDAQ:CING

Cingulate Q3 2026 Earnings Results & Report

Cingulate logo
$3.81 -0.49 (-11.40%)
As of 12:17 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Cingulate missed analyst earnings expectations in its Q3 2026 results, released November 13, 2026. The company reported EPS of -$0.53 versus the -$0.4325 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
After Market Closes
Conference Call
7:00 AM ET

Cingulate EPS Results

Actual EPS
-$0.53
Consensus EPS
-$0.4325
Beat/Miss
Missed by -$0.0975
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

Cingulate Revenue Results

Actual Revenue
N/A
Expected Revenue
$540 thousand
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cingulate Q3 2026 Earnings FAQ

Cingulate (NASDAQ:CING) reported earnings of -$0.53 per share for Q3 2026, missing the consensus estimate of -$0.4325. The report was announced on Friday, November 13, 2026.

Cingulate Earnings Headlines

What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
Cingulate (NASDAQ:CING) Stock Gets Downgrade from Wall Street Zen
See More Cingulate Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cingulate? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cingulate and other key companies, straight to your email.

About Cingulate

Cingulate (NASDAQ:CING) is a clinical-stage biopharmaceutical company developing prescription treatments for attention-deficit/hyperactivity disorder (ADHD). The company’s approach is to improve how existing medicines are delivered over the course of the day.

Its lead candidate, CTx-1301, is an extended-release formulation of dexmethylphenidate designed to provide multiple timed releases of medication. Cingulate is also developing CTx-1302, another candidate for ADHD.

The company uses its proprietary Precision Timed Release drug-delivery platform to develop these candidates. Cingulate is based in the United States and is focused on advancing its therapies through clinical development.

View Cingulate Profile